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The Lymphatic Network
The lymphatic vasculature consists of a network of lymph ves-
sels whose main function is to return protein-rich interstitial fluid 
to the circulating blood. Fluid, macromolecules, and cells, such 
as leukocytes and activated antigen-presenting cells, enter the 
lymphatic system through the blind-ended lymphatic capillar-
ies. From here, lymph is transported toward collecting lymphatic 
vessels and is returned to the blood circulation in the jugular 
area through the lymphaticovenous junctions.1 On its way, lymph 
is filtered through the lymph nodes, where foreign particles 
taken up by antigen-presenting cells initiate specific immune 
responses.2 In the small intestine, lacteal lymphatic vessels inside 
the intestinal villi absorb the dietary fat released by enterocytes 
in the form of lipid particles called chylomicron. In addition to 
these physiologic functions, the lymphatic system contributes to 
pathologic conditions such as lymphedema, inflammatory dis-
eases, and tumor metastasis. Many studies have demonstrated 
the existence of proliferative peri- and intratumoral lymphatic 
vessels.3 Additionally, tumoral lymphangiogenesis correlates with 
an increase in metastases,4,5 and detection of lymphangiogenic 
growth factors is associated with poor prognosis in many human 
tumors.6-8
Similar to blood capillaries, lymphatic capillaries are thin-
walled, relatively large vessels composed of a single layer of endo-
thelial cells, but they are not covered by pericytes or smooth 
muscle cells and have an absent or poorly developed basement 
membrane.9 In addition, they lack tight junctions and adherens 
junctions, which allows easy access for fluid, macromolecules, 
and cells to enter the vessel lumen.10 Endothelial cells of lym-
phatic capillaries are oak leaf-shaped and are characterized by 
discontinuous vascular endothelial (VE)-cadherin–positive 
button-like junctions. Collecting lymphatic vessels downstream 
have continuous zipper-like junctions previously described in 
blood vessels.9 Initial lymphatics combine to form larger ves-
sels called precollectors and collectors, which in turn feed into 
four major groups of lymph nodes in the axillary and inguinal 
regions. Collecting lymphatic vessels have a smooth muscle cell 
layer, basement membrane, and valves.
Lymphatic Markers
Lymphatic vessels were first described in the beginning of the 
17th century; however, the first growth factors and molecular 
markers specific for these vessels were discovered only 10 to 15 y ago. 
These growth factors include Prox1, the main transcription fac-
tor implicated in lymphatic vasculature development;11 lymphatic 
vascular endothelial-cell hyaluronan receptor-1 (LYVE-1),12 a new 
homolog of CD44 glycoprotein that is a lymph-specific receptor 
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Hypoxia is known to be a major factor in the induction of 
angiogenesis during tumor development but its role in lym-
phangiogenesis remains unclear. Blood and lymphatic vas-
culatures are stimulated by the vascular endothelial family 
of growth factors – the veGFs. in this review, we investigate 
the role of hypoxia in the molecular regulation of synthe-
sis of the lymphangiogenic growth factors veGF-A, veGF-C, 
and veGF-D. Gene expression can be regulated by hypoxia 
at either transcriptional or translational levels. in contrast to 
strong induction of DNA transcription by hypoxia-inducible 
factors (HiFs), the majority of cellular stresses such as hypoxia 
lead to inhibition of cap-dependent translation of mRNA and 
downregulation of protein synthesis. Here, we describe how 
initiation of translation of VEGF mRNA is induced by hypoxia 
through an internal ribosome entry site (iReS)-dependent 
mechanism. Considering the implications of the lymphatic 
vasculature for metastatic dissemination, it is crucial to under-
stand the molecular regulation of lymphangiogenic growth 
factors by hypoxia to obtain new insights into cancer therapy.
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for hyal-
uronan;13 and podoplanin, a transmembrane glycoprotein mol-
ecule.14 Although the blood and lymphatic vascular systems are 
structurally related and function in concert, these lymphatic-spe-
cific markers have allowed investigation of the specific features 
of lymph vessels. Vascular endothelial growth factor receptor 3 
(VEGFR-3, also known as FLT-4) has primarily been described 
as an major marker of lymphatics15,16 because its expression in 
adults becomes restricted to the lymphatic endothelium.17-19 
However, recent studies have shown that VEGFR-3 is also upreg-
ulated on vascular endothelial cells in angiogenic sprouts and is 
present on vessels in tumors and wounds.20,21
Lymphangiogenesis in Pathology
In adult organisms, lymphangiogenesis takes place only in 
certain pathologic conditions. Abnormal function of the lym-
phatics is implicated in certain disease states, such as lymph-
edema, inflammation, immune diseases, and tumor metastasis.
Lymphedema is a disorder of the lymphatic vascular system 
characterized by impaired lymphatic return and swelling of the 
extremities. When the lymphatic system has been damaged dur-
ing surgery or radiation treatment, its capacity to absorb excess 
water and cells from the interstitial space is reduced. 
If the transport capacity of the lymphatic system is 
reduced such so that it cannot handle this increase in 
lymphatic load, an insufficiency of the lymphatic sys-
tem may occur. Lymphedema can be an unfortunate 
side effect of cancer treatment and is a chronic condi-
tion that, if ignored, can lead to disfigurement, immo-
bilization, and severe infections. Without treatment, 
the swelling may continue to increase.
Inflammation is thought to contribute to the devel-
opment and progression of various cancers, including 
lung,22 breast,23 gastrointestinal,24-26 ovarian,27 pros-
tate,28 skin,29 and liver cancers.30 Inflammatory breast 
cancer exhibits increased angiogenesis and lymphan-
giogenesis and has a higher metastatic potential than 
noninflammatory breast cancer.31 Blocking lymphan-
giogenesis in chronic inflammatory diseases may be an 
important means of ameliorating the severity of some 
of these pathologies.
The extent of lymph node metastasis is a major 
determinant of staging and prognosis of most human 
malignancies. Although the clinical significance of 
lymph node involvement is well documented, the 
molecular mechanisms that promote tumor spread 
into the lymphatic or blood vascular systems and wide-
spread dissemination are not well understood. Recent 
studies have provided a large body of evidence indi-
cating that newly visualized lymphatics facilitate the 
formation of metastases. High tumor interstitial fluid 
pressure is thought to promote tumor cell entry into 
lymphatic vessels that have lower fluid pressure.32,33 
Intratumoral lymphatic vessel growth often correlates 
with metastasis of human melanoma, breast, or head 
and neck cancers34-36 where tumor cells can be observed within 
lymphatic vessels, demonstrating that lymphatic vessel growth is 
important for tumor spread (Fig. 1).
Tumor Growth, Hypoxia, and Lymphangiogenesis
As solid tumors grow, the cells within the expanding mass 
frequently become hypoxic because of the increasing distance 
from the nearest blood vessels. Without an adequate vascular 
supply, solid tumors can grow only to a critical size of 1–2 mm 
(approximately 106 cells), primarily due to a lack of oxygen and 
nutrients.37 A number of studies have been performed to charac-
terize and ultimately inhibit tumor angiogenesis. However, since 
hypoxia also regulates the expression of lymphangiogenic factors, 
it is crucial to consider tumor hypoxia and tumor lymphangi-
ogenesis as two tightly interlocked phenomena. In contrast to 
blood vessels, the lymphatic vasculature does not promote tumor 
growth by providing key elements for cell survival (i.e., oxy-
gen and nutrients), but allows metastatic dissemination of solid 
tumors through lymph nodes and finally to distant organs.38,39 
The lymphatic network is not merely an alternative vehicle to 
blood vessels for dissemination, but actually constitutes the main 
Figure  1. Crosstalk between tumor hypoxia and the lymphatic and blood vascu-
latures. Hypoxic tumor cells (blue) near pre-existing blood and lymphatic vessels 
secrete angiogenic and lymphangiogenic growth factors such as veGF-A, -C, and 
–D. Blood vessels bring oxygen and nutriments to tumor cells, whereas lymphat-
ics drain debris and provide new routes for tumor metastasis. Lymphatic metastatic 
tumor cells maintain lymphangiogenic growth factors synthesis in this poorly oxy-
genated environment to promote lymph node lymphangiogenesis and establish 
the “metastatic niche.”
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vascular system implicated in dissemination because lymphatic 
vessels have an optimal structure for tumor cell invasion. Indeed, 
the main difference between blood and lymphatic networks is the 
structure and permeability of their capillaries: whereas lymphatic 
capillaries are thin-walled, relatively large vessels, composed of 
a single layer of endothelial cells, lymphatic capillaries are not 
ensheathed by pericytes or smooth muscle cells and have little 
or no basement membrane.3 As a result of this high permeabilty, 
tumor cells can spread more easily in lymphatics than in blood 
vessels. Moreover, this invasion is also not just a passive process 
as tumors induce growth of new lymphatic vessels in draining 
lymph nodes and enlargment of lymphatic endothelium before 
metastasis. This remodelling of lymph nodes potentially con-
tributes to the migration, implantation, or survival of metastatic 
tumor cells by inducing a specific tumor microenvironment. 
Thus, a hypoxic tumor will not only ensure its survival through 
activation of angiogenesis but will also become more aggres-
sive. This dual regulation of blood and lymphatic vasculature by 
hypoxia during tumor growth impairs therapeutic efficacy. First, 
there is real crosstalk between the tumor and blood and lym-
phatic endothelial cells. Blood vessel endothelial cells produce 
lymphangiogenic factors such as vascular endothelial growth fac-
tor C (VEGFC), fibroblast growth factor 2 (FGF2), and plate-
let-derived growth factors (PDGFs) to facilitate tumor-induced 
lymphangiogenesis.40 Both endothelial cell types produce matrix 
metalloproteinases that promote tumor spreading. Lymphatic 
endothelial cells (LECs) also express the CCL21 chemokine that 
is physiologically implicated in dendritic cell mobilization41 and 
interacts with the CCR7 receptor expressed by many tumors to 
stimulate lymphatic dissemination.42 Several treatments have 
been developed specifically to inhibit tumor angiogenesis (e.g., 
Avastin) and therefore suppress tumor oxygenation and destroy 
tumor cells. However, these drugs also target lymphangiogenesis 
and would generate severe tumor hypoxia, which induces overex-
pression of lymphangiogenic factors and increased tumor dissem-
ination. This cross talk between hypoxia and the two vascular 
systems and the resultant spread of the tumor can in part explain 
the failure of antiangiogenic drugs in cancer treatment (Fig. 1).
A key feature of the lymphatic system is its hypoxic environ-
ment as lymphatic vessels do not transport red blood cells. Lymph 
vessels are often located in remote areas away from oxygen-car-
rying blood vessels and are therefore exposed to a milieu with 
very low oxygen levels. Tumor cells have to adapt to this hostile 
hypoxic environment in order to spread to the lymph nodes.43-45
Normoxia is defined as a milieu where the O
2
 concentration 
is sufficient to ensure aerobic metabolism of cells, the basis of 
eukaryotic physiology.46 In contrast, hypoxia is an environment 
where the aerobic metabolism of cells is inhibited due to a lack of 
oxygen. The major cellular response to hypoxia is stabilization of 
hypoxia-inducible factor 1(HIF1). HIF1 is a transcription factor 
that controls the expression of a battery of more than 40 target 
genes.47-49 It is composed of an α subunit that is constitutively 
expressed and a β subunit that is subject to rapid ubiquitination 
and proteasomal degradation under normoxic conditions.50 The 
molecular basis for this regulation is the O
2
-dependent hydrox-
ylation of proline residues 402 and 564 in HIF-1α by any one 
of three enzymes in mammals that have been designated prolyl 
hydroxylase-domain proteins or HIF-1α prolyl hydroxylases.51,52 
Prolyl hydroxylation of HIF-1α is required for binding of the von 
Hippel–Lindau tumor suppressor protein (VHL), which is the 
recognition component of an E3 ubiquitin-protein ligase that tar-
gets HIF-1α for proteasomal degradation.53,54 Hypoxia has been 
shown to regulate not only angiogenesis, but also lymphangio-
genesis by promoting overexpression of specific lymphangiogenic 
factors (e.g., VEGF-C) and growth factors that are shared by the 
vascular and the lymphatic vasculature (e.g., VEGF-A, FGF2). 
In this review we provide an overview of the link between lym-
phangiogenic factors and hypoxia and the consequences of this 
relationship in a well-known hypoxic pathology: the develop-
ment and dissemination of solid tumors.
Hypoxia-Induced Molecular Regulation of VEGFs
The VEGF family is composed of growth factors involved in 
vascular development. This family includes VEGF-A, -B, -C, -D, 
and -E, and placental growth factor.55 All members of this fam-
ily stimulate proliferation and migration of endothelial cells in 
vitro. These proteins bind and activate specific receptors on the 
endothelial cell surface: VEGF recognizes VEGFR-1 (Flt-1) and 
VEGFR-2 (KDR/Flk-1); placental growth factor and VEGF-B 
recognize VEGFR-1; and VEGF-C and VEGF-D recognize 
VEGFR-2 and VEGFR-3 (Flt-4). Lymphangiogenesis is induced 
by VEGFs that promote angiogenesis (VEGF-A) or angiogenesis 
and lymphangiogenesis (VEGF-C and VEGF-D).
Hypoxia-induced gene expression was first described as a tran-
scriptional mechanism mediated by hypoxia-responsive elements 
(HREs) present in the promoter region of different genes that 
are targets of the hypoxia-induced transcription factors (HIFs). 
In particular, a functional HRE has been identified within the 
5′ flanking region element of the human VEGFA gene56,57 that is 
the target of both HIF1 and HIF2.58 This HRE allows transcrip-
tional induction of VEGFA by hypoxia in several physiologic (i.e., 
wound healing, inflammation) and pathologic (i.e., ischemia, 
tumor development) states.
In addition to its transcriptional effects, hypoxia also regulates 
gene expression post-transcriptionally at the levels of mRNA sta-
bility and translation. An important class of mRNAs is stabilized 
by hypoxia: the so-called AU-rich mRNAs that bear AU-rich 
elements (AREs) in their 3′ untranslated regions (3′UTR).59,60 
AREs are found in mRNAs of most genes coding for cytokines, 
growth factors, and proto-oncogenes (7–8% of the transcribed 
genome), indicating that the stabilization of such mRNAs in 
hypoxic conditions has important consequences regarding cell 
pathophysiology. In particular, angiogenic cytokines including 
VEGF-A are regulated by this mechanism.61 mRNA stabiliza-
tion is controlled by the binding of HuR protein to the ARE 
in cooperation with polyA-binding protein interacting protein 2 
(PAIP2).62 One proposed mechanism is that HuR acts in com-
petition with destabilizing proteins such as AUF1 or tristetrap-
rolin (TTP) to bind to the ARE.61 Another emerging concept 
is that HuR counteracts the binding of microRNAs to mRNA 
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3′UTRs.63 In the case of Vegfa mRNA, the HuR binding site 
overlaps with the binding site of miR-200b, thus HuR antago-
nizes the suppressive effect of this microRNA.63
Hypoxia also strongly regulates gene expression at the trans-
lational level. First, it silences global cell translation by inhibit-
ing mRNA cap-dependent translation through inactivation of 
mTOR kinase. This results in hypophosphorylation of the 4E-BP 
protein, which then sequesters the cap-binding factor eIF4E.64,65 
In addition, hypoxia induces phosphorylation of the initiation 
factor eIF2a by activation of PERK kinase, which also gener-
ates translational blockade.66 Two major alternative mechanisms 
are able to overcome this global inhibition of translation that is 
induced by hypoxia: upstream open reading frames (uORFs) and 
internal ribosome entry sites (IRESs). uORFs are a key element of 
translational control in response to stress. These elements precede 
the initiation codon of the mRNA main coding regions and are 
present in approximately 40–50% of mRNAs. They are primar-
ily translational inhibitors when eIF2a is dephosphorylated and 
the complex of initiator tRNA with eIF2 and GTP is available 
for translation initiation. In contrast, they allow the ribosome to 
scan and reach the initiation codon of the main coding sequence 
in conditions of stress when eIF2a is phosphorylated.67
IRESs are RNA structural elements present in the 5′ non-
translated regions of a small number of mRNAs that allow 
recruitment of the ribosome to a site that is a considerable dis-
tance from the cap structure, most frequently in the presence 
of trans-acting factors.64,68 The majority of identified IRESs are 
found in mRNAs of proteins associated with the control of cell 
growth and death, including growth factors, proto-oncogenes, 
and proteins required for apoptosis.65,69 IRES-dependent trans-
lation is cap-independent and, in the case of cellular mRNAs, 
independent of eIF2a phosphorylation; this allows translation to 
occur in stress conditions.64,70 Notably, HIF1α mRNA possesses 
an IRES, suggesting that these structure are crucial for trans-
lational regulation occurring under hypoxia. IRESs have also 
been identified in the mRNAs of three major lymphangiogenic 
growth factors, FGF2, VEGF-A, and VEGF-C.71,72 Interestingly, 
these IRESs are activated in hypoxic conditions, resulting in 
translational induction of these factors.45,73 The regulation of 
VEGF-A and -C expression and their relationship with hypoxia 
is discussed below.
VEGF-A
VEGF-A, also called vascular permeability factor, is a homodi-
meric glycoprotein with a molecular weight of approximately 45 
kDa. At least 9 VEGF isoforms exist as a result of alternative pat-
terns of splicing.74 Three of these, containing 121, 165, and 189 
amino acids respectively, are preferentially expressed by VEGF-A 
producing cells75-77 Each of these isoforms contributes to forma-
tion of a VEGF-A gradient essential for the proper migration 
of ECs/LECs during angiogenesis or lymphangiogenesis. The 
larger species, VEGF-165, VEGF-189, and VEGF-206, are basic 
and bind to isolated heparin and heparin proteoglycans distrib-
uted on cellular surfaces and extracellular matrices whereas the 
smaller species, VEGF-121, is acidic and is freely diffusible.78 
Although VEGF-A is mainly known as a growth factor that plays 
an essential role in physiologic and pathologic angiogenesis dur-
ing both development and adulthood,79 it also has prolymphan-
giogenic properties.80,81 The proangiogenic activity of VEGF-A is 
mediated by interaction with a high-affinity VEGFR2 receptor, 
whereas the prolymphangiogenic activity is promoted by binding 
to the VEGFR2/R3 heterodimeric receptor.
In addition to its transcriptional upregulation during hypoxia, 
is probably the most highly post-transcriptionally regulated 
factor.74 The gene structure of VEGF-A has been predicted in 
silico (Fig. 2A). VEGFA mRNA contains two IRESs72 located 
upstream of the alternative initiation codons CUG and AUG that 
are responsible for synthesis of alternative isoforms of VEGF-A.74 
Figure 2. Schematic representation of VEGF-A, -C, and -D mRNAs. (A) VEGF-A mRNA is characterized by a long 5′UTR (1038 nt) containing two internal 
ribosome entry sites (iReSs) (A and B). The VEGF-A gene encodes multiple isoforms generated by mRNA splicing of four constitutive and four alternative 
exons. (B) VEGF-C mRNA possesses a GC-rich 5′UTR containing one iReS. The secondary structure of veGF-C iReS has been determined by shape analysis 
and contains 2 motifs (indicated by boxes) showing a similar reactivity pattern between human and mouse mRNA. (C) Similar to VEGF-C, the VEGF-D 
mRNA is generated from 7 exons.
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Both IREs are activated by hypoxia.73 Vegfa IRESs are differen-
tially regulated by an upstream ORF and by binding of Mir16 
to the 3′UTR.82,83 A study of VEGF-A IRES trans-acting fac-
tors revealed tight regulation by both positive regulators activated 
by hypoxia (e.g., MAPK3 kinase) and negative regulators that 
are inhibited during this stress (e.g., DEAD-box RNA helicase 
6).84 Another mechanism implicated in translation regulation of 
VEGF-A is riboswitch. Riboswitch refers to the ability of mRNAs 
to alter their folding structure and hence rate of translation in 
response to an environmental modification. During hypoxia, 
intracellular accumulation of heterogeneous nuclear ribonu-
cleoprotein L (hnRNP L) promotes an active conformation and 
increases the rate of translation of VEGF-A mRNA.85 VEGF-A 
expression is strongly regulated at the level of mRNA stability, 
a process primarily mediated by the AREs present in the Vegfa 
mRNA. Indeed, the Vegfa mRNA is destabilized by several pro-
teins including AU-rich element RNA-binding protein 1 (AUF1, 
also known as hnRNPD) and tristetraprolin (TTP), which target 
the AREs.61 Destabilization of Vegfa mRNA by TTP is respon-
sible for its antiangiogenic activity.86 In contrast, Vegfa mRNA is 
stabilized by hypoxia.60 This process is mediated by binding of 
the RNA stabilizing protein HuR and its partner PAIP2 to the 
AREs, which prevents binding of the destabilizing proteins.60,61 
Interestingly, the MDM2 protein, which is translocated from the 
nucleus to the cytoplasm under hypoxic conditions, increases 
Vegfa mRNA stabilization.87 Vegfa mRNA stability is thus con-
trolled by interplay between stabilizing and destabilizing proteins 
that compete for binding to the AREs. Moreover, it has been 
proposed that export of VEGF-A mRNA from the nucleus and its 
loading onto ribosomes can be increased during hypoxia by extra-
nuclear shuttling of mRNA-binding proteins such as hnRNP L 
and A1, which also regulate VEGF-A mRNA stability.88 These 
mechanisms, combined with transcriptional regulation induced 
by HIFs, allow fast and massive overexpression of VEGF-A in 
response to hypoxia.
VEGF-C
The VEGF-C/VEGFR3 signaling pathway is the major 
pathway implicated in lymphangiogenesis. First identified in 
1996,89 VEGF-C is produced as a precursor protein that is acti-
vated by intracellular proprotein convertases.89,90 The secreted 
disulphide-linked VEGF-C subunits only bind VEGFR-3, but 
the factor is further proteolyzed in the extracellular environment 
by plasmin and other proteases to generate non–disulfide-linked 
homodimeric proteins with high affinity for both VEGFR-2 and 
VEGFR-3.3,90 VEGF-C is crucial for the induction of prolifera-
tion, migration, and survival of endothelial cells.91 VEGF-C is 
also an essential chemotactic and survival factor during embry-
onic lymphangiogenesis; homozygous deletion of VEGF-C leads 
to complete absence of lymphatic vasculature in mouse embryos 
whereas VEGF-C+/− mice display severe lymphatic hypoplasia. 
In VEGF-C null mice, lymphatic endothelial cells initially dif-
ferentiate in the cardinal veins but fail to migrate and form pri-
mary lymph sacs.92 Although several studies have shown positive 
correlations between HIF-1α and VEGF-C in various can-
cers,93-95 for a long time the molecular mechanisms of hypoxia-
induced regulation of VEGF-C remained poorly understood. 
The likelihood of direct transcriptional regulation of VEGF-C 
by HIF1α is low because the VEGF-C promoter does not con-
tain a HRE sequence.96 Our recent work demonstrated the exis-
tence of a single IRES in the 5′UTR of both murine and human 
VEGF-C mRNA (Fig. 2B). We have demonstrated that VEGF-C 
IRES activity is upregulated in vivo during tumor growth in 
three murine models of carcinoma, similar to the IREs of FGF2 
and VEGF-A.45 Strikingly, we also observed that VEGF-C IRES 
activity increases under hypoxia in vitro, but the presence of 
HIF-1α is not required in cultured cells.
VEGF-D
Binding of VEGF-D, also called c-fos induced growth fac-
tor, to its receptor VEGFR-3 promotes lymphangiogenesis. 
The VEGF-D gene encodes 7 exons (Fig. 2C). Maturation of 
VEGF-D is similar to that of VEGF-C and occurs by protein 
cleavage in N and C-terminal regions. VEGF-D has been poorly 
studied because of the lack of a phenotype resulting from its 
depletion in mice. Recent reports have shown that overexpres-
sion of VEGF-D induces tumor lymphangiogenesis and pro-
motes lymphatic metastasis in mouse tumor models.97 However, 
few clinical studies have investigated the association between the 
expression of VEGF-D and lymphatic metastasis. VEGF-D over-
expression correlates with an increase in lymphatic vessel growth 
and lymphatic metastasis.39 Recent studies suggest that VEGF-D 
is necessary for for the entry of tumor cells into the lymphatic 
system that results in metastasis.98 VEGF-D promotes structural 
changes in tumor-draining lymphatic vessels and induces vaso-
dilatation. VEGF-D also increases the endothelial response to 
prostaglandin E2 (PGE2) by inhibiting the prostaglandin dehy-
drogenases (PGDH).99,100
The role of hypoxia in the promotion of VEGF-D expres-
sion has not been clearly established. Recent studies have dem-
onstrated correlations between VEGF-D and HIF-1α expression 
in invasive breast ductal carcinoma101 and in resected esophageal 
squamous cell carcinoma.102
These findings revealed that expression of lymphangiogenic 
factors is tightly linked to hypoxia, which activates their expres-
sion at both transcriptional and translational levels. It is now well 
known that, at least in solid tumors, hypoxia is a major compo-
nent of the tumor microenvironment and induces critical changes 
in tumor cell metabolism, angiogenesis, and lymphangiogenesis.
Concluding Remarks and Perspectives
The lymphatic vasculature has long been considered the poor 
relation of the blood vasculature. Compared with the vascular 
network, which provides both oxygen and nutrients and is there-
fore obviously necessary for life, the lymphatic system appeared 
to be a less important vascular network. In addition, until 
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recently it was challenging to differentiate lymph from blood 
vessels due to lack of a specific marker. Recently, however, the 
lymphatic system has emerged as a crucial player during develop-
ment and in adulthood. Although it is implicated specifically in 
chronic inflammatory and vascular pathologies (such as psoriasis 
and lymphedema), it is also able to interact with blood vessels in 
cancer. Indeed, recent studies have highlighted hypoxia-induced 
regulation of lymphangiogenic factors in the tumor microenvi-
ronent. Understanding the molecular regulation of lymphangio-
genesis in a wide range of organs and pathologies might lead to 
new therapeutic solutions for diseases such as cancer.
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